

22nd July, 2021

| | |
|--|---|
| <p>BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001</p> <p><u>Scrip Code: 532300</u></p> | <p>National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex Bandra (E) Mumbai - 400 051</p> <p><u>NSE Symbol: WOCKPHARMA</u></p> |
|--|---|

Dear Sir/ Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') read with Schedule III of Listing Regulations, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 22nd July, 2021, inter-alia, have:

- (i) approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2021 and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company; and
- (ii) appointed Mr. Debashis Dey, Associate Member of the Institute of Company Secretaries of India (having Membership No. ACS 18118) as the Company Secretary and Compliance Officer w.e.f. 23rd July, 2021 and consequently relinquished Mr. Gajanand Sahu from the additional charge of Company Secretary and Compliance Officer (Acting) of the Company after the closure of the working hours on 22nd July, 2021, as requested by him. A brief particulars of Mr. Debashis Dey is enclosed as Annexure I.
- (iii) noted that Mr. Manas Datta, Chief Financial Officer of the Company has decided to pursue other responsibilities outside the Company and will be leaving the Company in the first week of September 2021 and thanked him for his valuable contribution over the past 7 years and wished him all success in his future endeavours.

Pursuant to Regulation 33 of the Listing Regulations, we enclose herewith the following:

- (i) Unaudited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2021; and Limited Review Report issued by B S R & Co. LLP., Statutory Auditors of the Company,
- (ii) A copy of the Press Release proposed to be issued in respect of the said Financial Results; and
- (iii) Extract of Unaudited Consolidated Financial Results for the quarter ended 30th June, 2021, being published in the Newspapers

The meeting of the Board of Directors commenced at 11.15 a.m. and concluded at 12.30 p.m.

Kindly take the same on record please.

Thanking you,

For **Wockhardt Limited**



Gajanand Sahu
Company Secretary
Encl: As above



Annexure I

The details required to be furnished pursuant to Regulation 30 of the Listing Regulations read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

| Sr. No. | Particulars | Details |
|---------|---|---|
| 1 | Reason for change viz. appointment, resignation, removal, death or otherwise | Appointment |
| 2 | Date of appointment/ cessation (as applicable) & term of appointment | 23 rd July, 2021 Full time employee of the Company governed by the standard terms of employment as per Company Policy. |
| 3 | Brief profile (in case of appointment); | <p>Mr. Debashis Dey is a member of the Institute of Company Secretaries of India with over seventeen years of professional experience in handling secretarial, legal, compliance matters of leading corporate houses including Sun Pharma, Piramal and JSW group, and have handled multiple primary/ capital market issues, corporate restructuring, joint ventures/ collaborations with Indian and foreign partners/ govt. bodies in the past.</p> <p>Prior to joining Wockhardt, Mr. Dey was the Company Secretary & Compliance Officer of Sun Pharma Advanced Research Company Limited, where, in addition to his secretarial and compliance roles, he was also heading the legal functions of the Company.</p> <p>Mr. Dey is Commerce and Law Graduate, MBA (Finance) and an Associate member of the Institute of Company Secretaries of India.</p> |
| 4 | Disclosure of relationships between directors (in case of appointment of a director). | Nil |